The emergence of bacterial strains resistant to current antibiotics highlights the need to explore new targets for antibiotic action. Peptidoglycan biosynthesis is one of the well-precedented targets for therapeutic antimicrobial agents. Phospho-Af-acetylmuramyl-pentapeptide translocase (also called translocase I) catalyzes the first reaction in the lipid cycle in bacterial peptidoglycan formation in vitro is relatively resistant to its action (IC50 of 100 /ig/ml), and the growth of mammaliancells is not severely affected at 1000 jag/ml. Liposidomycins potently inhibit Escherichia coli translocase I in vitro with an IC50 of 0.03>g/ml5), but they are not toxic in mice8 with that of tunicamycin and mureidomycin A. Liposidomycin B and mureidomycin A did not affect the formation of both lipid-linked sugars at the highest concentration tested, 400 /xg/ml, but tunicamycin inhibited Dol-P-glucose formation with an IC50 value of 5 /ig/ml (data not shown).
Undecaprenyl (pyro)phosphate JV-acetylglucosamine formation in the Bacillus subtilis membrane was dose-dependently inhibited by liposidomycin B, tunicamycin, and mureidomycin A, and their IC50 values were 400, 1, and more than 400/xg/ml, respectively (Fig. 2) . The IC50 values of the three antibiotics for undecaprenyl (pyro)phosphate 7V-acetylglucosamme formation were higher than those for Dol-PP-TV-acetylglucosamine formation, and a 20-fold difference was demonstrated with both liposidomycin B and tunicamycin between the two activities. The cause for the difference in the two activities waits for a further clarification.
Tunicamycin inhibited glycoprotein biosynthesis and multiplication of enveloped viruses such as Newcastle disease virus and vesicular stomatitis virus, but liposidomycin B and mureidomycin A did not at all at the highest concentration tested, 400 /zg/ml (data not shown). Such a resistancy to the action ofliposidomycin B at a cellular level has been reported with bacteria. Liposidomycin B exerts a strong inhibitory activity in vitro against translocase I5) and, in contrast, the antibacterial activity of liposidomycin B is limited8), and the reason has yet to be determined. (Received October 1, 1996) 
